Hospital Acquired infections Market Analysis

In-depth Analysis of Hospital Acquired infections Market Industry Landscape

The rise in diabetes cases has a significant impact on urological health. Diabetes not only leads to urinary tract infections (UTIs) and bladder issues but also affects blood flow, nerves, and sensory functions in the body, making urologic conditions worse. The International Diabetes Federation reported that around 463 million adults aged 20 to 79 had diabetes in 2019, and this number is projected to soar to 700 million by 2045. Moreover, in 2019, about 79% of adults with diabetes were living in low- and middle-income countries. Additionally, various factors like urinary tract infections, obesity, weight loss surgery, and family history contribute to kidney stone formation. Every year, over half a million people seek emergency care for kidney stone issues, and it's estimated that one in ten individuals will experience a kidney stone at some point in their lives. The increasing prevalence of diabetes and kidney stones leads to a surge in urinary tract infections (UTIs), subsequently driving up the demand for medications in the global urinary tract infection market.

Early identification and proper treatment are crucial for managing urinary tract infections in diabetic and kidney stone patients. These aspects are anticipated to fuel the growth of the global urinary tract infections market.

There's a notable surge in the development of innovative antibiotics for treating urinary tract infections, contributing to market growth. For instance, in August 2020, researchers at California Polytechnic State University unveiled a fresh category of antibiotics targeting bacterial iron acquisition for urinary tract infections at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo. Furthermore, the US Food and Drug Administration approved Recarbrio (imipenem, cilastatin, and relebactam) by Merck & Co., Inc. in July 2019. This antibacterial drug is aimed at treating adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

In August 2017, the FDA sanctioned a new antibiotic combination, Vabomere, for cUTI treatment. This drug contains meropenem and the novel beta-lactamase inhibitor vaborbactam. According to the FDA, Vabomere exhibited better results than another antibiotic/beta-lactamase combination drug in a randomized phase 3 clinical trial involving 545 cUTI patients, including those with acute pyelonephritis (kidney infection). The launch of these more effective combination drugs is projected to amplify growth in the urinary tract infection market.